BRAF and neoplasm: Due to the small number of patients analyzed and the intensive treatment regimens applied in all patients, it is impossible to determine whether the unfavorable tumor control after DpR is specific for BRAF-MT mCRC in general or for BRAF-MT mCRC treated with FOLFOXIRI regimens.